[go: up one dir, main page]

WO2004083381A3 - Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants - Google Patents

Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants Download PDF

Info

Publication number
WO2004083381A3
WO2004083381A3 PCT/US2004/007220 US2004007220W WO2004083381A3 WO 2004083381 A3 WO2004083381 A3 WO 2004083381A3 US 2004007220 W US2004007220 W US 2004007220W WO 2004083381 A3 WO2004083381 A3 WO 2004083381A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
growth factor
factor receptor
fibroblast growth
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/007220
Other languages
French (fr)
Other versions
WO2004083381A2 (en
Inventor
Michael J Econs
Kenneth E White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of WO2004083381A2 publication Critical patent/WO2004083381A2/en
Anticipated expiration legal-status Critical
Publication of WO2004083381A3 publication Critical patent/WO2004083381A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to novel fibroblast growth factor receptor-1 polynucleotides and polypeptides, and to compositions, uses and methods thereof. Further, this invention relates to agonists and antagonists of fibroblast growth factor receptor-1 polypeptides, as well as to methods of treatment of disorders arising from altered fibroblast growth factor receptor-1 polynucleotides and polypeptides.
PCT/US2004/007220 2003-03-13 2004-03-10 Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants Ceased WO2004083381A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45439503P 2003-03-13 2003-03-13
US60/454,395 2003-03-13

Publications (2)

Publication Number Publication Date
WO2004083381A2 WO2004083381A2 (en) 2004-09-30
WO2004083381A3 true WO2004083381A3 (en) 2007-07-05

Family

ID=33029878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007220 Ceased WO2004083381A2 (en) 2003-03-13 2004-03-10 Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants

Country Status (1)

Country Link
WO (1) WO2004083381A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342553B (en) * 2008-04-29 2016-10-04 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods.
AU2013206768B2 (en) * 2008-04-29 2016-03-31 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (en) 2009-05-05 2022-05-03 Amgen Inc Mutant fgf21 polypeptides, fusion polypeptide, multimer, pharmaceutical composition, isolated nucleic acid, vector and host cell
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
JP2013512672A (en) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド Human FGFR1c, human β-croto-, and binding proteins that bind to both human FGFR1c and human β-croto-
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
WO2012015674A1 (en) 2010-07-26 2012-02-02 Eli Lilly And Company THERAPEUTIC USES OF AN FGFR1c ANTIBODY
CN116688095B (en) * 2023-03-08 2024-09-10 中国人民解放军海军军医大学 Anti-herpesvirus effect of receptor tyrosine kinase FGFR1 and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
WHITE ET AL.: "Mutations that Cause Osteoglophonic Dysplasia Define Novel Roles for FGFR1 in Bone Elongation", AM. J. HUM. GENET., vol. 76, 2005, pages 361 - 367, XP003015129 *
YU ET AL.: "Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23", ENDOCRINOLOGY, vol. 146, no. 11, 2005, pages 4647 - 4656, XP003015130 *
YU ET AL.: "FGF23 and disorders of phosphate homeostasis", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 16, 2005, pages 221 - 232, XP004874956 *

Also Published As

Publication number Publication date
WO2004083381A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
EP1499308A4 (en) Tri-substituted heteroaryls and methods of making and using the same
WO2006060513A3 (en) Toll like receptor 3 antagonists, methods and uses
WO2004108133A3 (en) Modulators of vr1 receptor
WO2003020212A3 (en) Treatment for central nervous system disorders
WO2004021989A3 (en) Imidazolopyridines and methods of making and using the same
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
MX249034B (en) Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions.
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
ATE548363T1 (en) 3,5-DISUBSTITUTED PYRID-2-ONES, WHICH ARE SUITABLE AS INHIBITORS OF THE TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
WO2004029087A3 (en) Bitter taste receptors
WO2006014618A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
WO2004083381A3 (en) Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
WO2004005262A8 (en) New neuropeptide y y5 receptor antagonists
WO2004073628A3 (en) Novel compounds
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
WO2004047771A3 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2003070904A3 (en) Human rnase iii and compositions and uses thereof
WO2002070001A3 (en) Use of lp82 to treat hematopoietic disorders
WO2004032864A3 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
MX2007006754A (en) Indenyl derivatives and use thereof for the treatment of neurological disorders.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase